MetLife Investment Management’s Entrada Therapeutics TRDA Stock Holding History

MetLife Investment Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Hold	17,802	–	–	﹤0.01%	2173
2025 Q4	$183K	Buy	17,802 +10,642	+149%	+$89.7K	﹤0.01%	2319
2025 Q3	$41.5K	Sell	7,160 -9,169	-56%	-$53.6K	﹤0.01%	2804
2025 Q2	$110K	Hold	16,329	–	–	﹤0.01%	2494
2025 Q1	$148K	Hold	16,329	–	–	﹤0.01%	2357
2024 Q4	$282K	Buy	16,329 +1,731	+12%	+$31.4K	﹤0.01%	2116
2024 Q3	$233K	Hold	14,598	–	–	﹤0.01%	2209
2024 Q2	$208K	Buy	14,598 +2,904	+25%	+$41.3K	﹤0.01%	2217
2024 Q1	$166K	Hold	11,694	–	–	﹤0.01%	2298
2023 Q4	$176K	Hold	11,694	–	–	﹤0.01%	2304
2023 Q3	$185K	Hold	11,694	–	–	﹤0.01%	2263
2023 Q2	$177K	Buy	+11,694	New	+$161K	﹤0.01%	2352

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's TRDA Position: Q1 2026 in Review

MetLife Investment Management held its Entrada Therapeutics (TRDA) position steady in Q1 2026 at 17,802 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #2173.

MetLife Investment Management first reported a position in TRDA in Q2 2023 and has held it in 12 quarters since. The position peaked at $282K in Q4 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

MetLife Investment Management held 17,802 shares of Entrada Therapeutics worth $225K as of Q1 2026.
MetLife Investment Management left its Entrada Therapeutics share count unchanged in Q1 2026.
Entrada Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2173 holding.
MetLife Investment Management first reported a position in Entrada Therapeutics in Q2 2023 and has held it in 12 quarters since.
MetLife Investment Management's Entrada Therapeutics position peaked at $282K in Q4 2024.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.